These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25442437)

  • 1. Superiority of ticagrelor over clopidogrel in patients after cardiac arrest undergoing therapeutic hypothermia.
    Moudgil R; Al-Turbak H; Osborne C; Hibbert B; So DY; Le May MR;
    Can J Cardiol; 2014 Nov; 30(11):1396-9. PubMed ID: 25442437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction.
    Bednar F; Kroupa J; Ondrakova M; Osmancik P; Kopa M; Motovska Z
    J Thromb Thrombolysis; 2016 May; 41(4):549-55. PubMed ID: 26340851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
    Storey RF; Bliden KP; Ecob R; Karunakaran A; Butler K; Wei C; Tantry U; Gurbel PA
    J Thromb Haemost; 2011 Sep; 9(9):1730-7. PubMed ID: 21707911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention.
    Choi KN; Jin HY; Shin HC; Park YA; Seo JS; Jang JS; Yang TH; Kim DK; Kim DS
    Am J Cardiol; 2017 Jul; 120(2):201-206. PubMed ID: 28554486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
    Chen Y; Dong W; Wan Z; Li Z; Cong H; Hong T; Yin T
    Int J Cardiol; 2015 Dec; 201():545-6. PubMed ID: 26325437
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Dehghani P; Lavoie A; Lavi S; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN
    Am Heart J; 2017 Oct; 192():105-112. PubMed ID: 28938956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
    Bliden KP; Tantry US; Storey RF; Jeong YH; Gesheff M; Wei C; Gurbel PA
    Am Heart J; 2011 Jul; 162(1):160-5. PubMed ID: 21742103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
    Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
    Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
    Steblovnik K; Blinc A; Mijovski MB; Fister M; Mikuz U; Noc M
    Circulation; 2016 Dec; 134(25):2128-2130. PubMed ID: 27994027
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
    Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
    Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
    Lhermusier T; Voisin S; Murat G; Mejean S; Garcia C; Bataille V; Lipinski MJ; Carrié D; Sié P
    Int J Cardiol; 2014 Jul; 174(3):874-6. PubMed ID: 24820749
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.
    Ibrahim K; Christoph M; Schmeinck S; Schmieder K; Steiding K; Schoener L; Pfluecke C; Quick S; Mues C; Jellinghaus S; Wunderlich C; Strasser RH; Kolschmann S
    Resuscitation; 2014 May; 85(5):649-56. PubMed ID: 24555950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center.
    Dalal JJ; Digrajkar A; Gandhi A
    Indian Heart J; 2016; 68(5):624-631. PubMed ID: 27773400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
    Schneider DJ; Chava S
    Coron Artery Dis; 2016 May; 27(3):185-90. PubMed ID: 26751426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial.
    Sardella G; Calcagno S; Mancone M; Lucisano L; Pennacchi M; Stio RE; Placentino F; Di Roma A; Cavallo E; Palmirotta R; Guadagni F; Fedele F
    Int J Cardiol; 2015 Sep; 194():60-2. PubMed ID: 26011265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.